Synopsis
Synopsis
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Actimoxi
2. Amoxicillin
3. Amoxicillin Anhydrous
4. Amoxicillin Monopotassium Salt
5. Amoxicillin Monosodium Salt
6. Amoxicillin Sodium
7. Amoxicillin, (r*)-isomer
8. Amoxicilline
9. Amoxil
10. Amoxycillin
11. Brl 2333
12. Brl-2333
13. Brl2333
14. Clamoxyl
15. Clamoxyl G.a.
16. Clamoxyl Parenteral
17. Hydroxyampicillin
18. Penamox
19. Polymox
20. Trimox
21. Wymox
1. 61336-70-7
2. Larotid
3. Polymox
4. Trimox
5. Utimox
6. Wymox
7. Clamoxyl
8. Amoxil
9. Amoxipen
10. Moxaline
11. Amodex
12. Zimox
13. Robamox
14. Dispermox
15. Novabritine
16. Hiconcil
17. Imacillin
18. Amoxycillin Trihydrate
19. Brl 2333
20. Moxatag
21. 61336-70-7 (hydrate)
22. Topramoxin
23. Amoxyke
24. Atoksilin
25. Demoksil
26. Largopen
27. Moksilin
28. Promoxil
29. Remoxil
30. Damoxy
31. 804826j2hu
32. (2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid Trihydrate
33. Amoksicillin
34. Kentrocyllin
35. Zamocilline
36. Alfamox
37. Amophar
38. Amoxidal
39. Amoxillat
40. Amoxina
41. Amoxine
42. Flemoxine
43. Galenamox
44. Gramidil
45. Himinomax
46. Izoltil
47. Matasedrin
48. Metifarma
49. Pacetocin
50. Pamocil
51. Paradroxil
52. Siganopen
53. Simplamox
54. Sintopen
55. Velamox
56. Zamocillin
57. Amoran
58. Ciblor
59. Amoxicillin Hydrate
60. Amoxi-wolff
61. Uro-clamoxyl
62. Brl-2333
63. Amoxi-diolan
64. Amox
65. Amoksicillin Forte
66. A-gram
67. Dura Ax
68. Amoxicillin [usan]
69. Amoxicillin-ratiopharm
70. Drg-0075
71. Amoxicillin (as Trihydrate)
72. (2s,5r,6r)-6-((r)-2-amino-2-(4-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid Trihydrate
73. (2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid;trihydrate
74. Amoxicillin Hydrate (1:3)
75. Neotetranase
76. Sawacillin
77. Pasetocin
78. Eupen
79. Amoxil Trihydrate
80. Unii-804826j2hu
81. Alpha-amino-p-hydroxybenzylpenicillin Trihydrate
82. Amoxipen Trihydrate
83. Dispermox (tn)
84. Moxaline Trihydrate
85. Pasetocin (tn)
86. (2s,5r,6r)-6-{[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid Trihydrate
87. Amoxicillin (usp)
88. Amoxicillin Pulsys
89. Amoxicillin-trihydrat
90. Amoxicilline (inn)
91. Amoxil (tn)
92. Amoxicillin [usan:usp:inn:ban:jan]
93. (2s,5r,6r)-6-[(2r)-2-amino-2-(4-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid
94. Amoxicillin [vandf]
95. Amoxicillin Hydrate (jp17)
96. Amoxicillin [usp-rs]
97. (2s,5r,6r)-6-((r)-(-)-2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid Trihydrate
98. Dtxsid2022599
99. Chebi:51254
100. Amoxicillin [orange Book]
101. Amoxicillin Hydrate [jan]
102. Apc-111
103. Amoxicillin [usp Impurity]
104. Amoxicillin [usp Monograph]
105. Amoxicillin Trihydrate [mi]
106. Prevpac Component Amoxicillin
107. Talicia Component Amoxicillin
108. Mfcd00072029
109. S5298
110. Amoxicillin Trihydrate [vandf]
111. Augmentin Component Amoxicillin
112. Akos015896673
113. Amoxicillin Trihydrate [mart.]
114. Amoxicillin Component Of Prevpac
115. Amoxicillin Component Of Talicia
116. Amoxicillin Trihydrate [who-dd]
117. Amoxicillin Trihydrate [who-ip]
118. Ccg-268878
119. Ks-5338
120. Amoxicillin Component Of Augmentin
121. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 6-((amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, Trihydrate (2s-(2alpha,5alpha,6beta(s*)))-
122. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 6-((amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, Trihydrate(2s-(2alpha,5alpha,6beta(s*)))-
123. Amoxicillin Trihydrate [green Book]
124. Amoxicillin Trihydrate [ep Monograph]
125. Clavulox Component Amoxicillin Trihydrate
126. D00229
127. Amoxicillinum Trihydricum [who-ip Latin]
128. A833170
129. Amoxicillin Trihydrate Component Of Clavulox
130. Q27122483
131. Amoxil Trihydrate;amoxipen Trihydrate;moxaline Trihydrate
132. Amoxicillin Trihydrate, Vetranal(tm), Analytical Standard
133. Amoxicillin, United States Pharmacopeia (usp) Reference Standard
134. Amoxicillin Trihydrate, British Pharmacopoeia (bp) Reference Standard
135. Amoxicillin Trihydrate, European Pharmacopoeia (ep) Reference Standard
136. Amoxicillin Trihydrate, Pharmaceutical Secondary Standard; Certified Reference Material
137. (2s,5r)-6-[[2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid Trihydrate
138. (2s,5r,6r)-6-((r)-(-)-2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicycl(3.2.0)heptane-2-carboxylic Acid Trihydrate
139. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 6-(((2r)-amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, Trihydrate, (2s,5r,6r)-
140. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 6-((amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, Trihydrate(2s-(2.alpha.,5.alpha.,6.beta.(s*)))-
141. 6beta-[(2r)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic Acid Trihydrate
142. Amoxicillin Trihydrate For Performance Verification, European Pharmacopoeia (ep) Reference Standard
| Molecular Weight | 419.5 g/mol |
|---|---|
| Molecular Formula | C16H25N3O8S |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 4 |
| Exact Mass | 419.13623594 g/mol |
| Monoisotopic Mass | 419.13623594 g/mol |
| Topological Polar Surface Area | 161 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 590 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 4 |
| 1 of 6 | |
|---|---|
| Drug Name | Amoxil |
| Active Ingredient | Amoxicillin |
| Dosage Form | Tablet; Capsule; Tablet, chewable; For suspension |
| Route | Oral |
| Strength | 875mg; 50mg/ml; 200mg/5ml; 250mg; 125mg/5ml; 400mg/5ml; 125mg; 500mg; 250mg/5ml |
| Market Status | Prescription |
| Company | Dr Reddys Labs |
| 2 of 6 | |
|---|---|
| Drug Name | Larotid |
| PubMed Health | Amoxicillin (By mouth) |
| Drug Classes | Antibiotic |
| Drug Label | MOXATAG (amoxicillin extended-release) tablets for oral administration are provided as blue film-coated, oval shaped tablets that contain 775 mg of amoxicillin as the trihydrate and are printed with MB-111 on one side in black edible ink. Amoxi... |
| Active Ingredient | Amoxicillin |
| Dosage Form | For suspension |
| Route | Oral |
| Strength | 250mg/5ml; 125mg/5ml |
| Market Status | Prescription |
| Company | Dr Reddys Labs |
| 3 of 6 | |
|---|---|
| Drug Name | Moxatag |
| Active Ingredient | Amoxicillin |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | 775mg |
| Market Status | Prescription |
| Company | Pragma Pharms |
| 4 of 6 | |
|---|---|
| Drug Name | Amoxil |
| Active Ingredient | Amoxicillin |
| Dosage Form | Tablet; Capsule; Tablet, chewable; For suspension |
| Route | Oral |
| Strength | 875mg; 50mg/ml; 200mg/5ml; 250mg; 125mg/5ml; 400mg/5ml; 125mg; 500mg; 250mg/5ml |
| Market Status | Prescription |
| Company | Dr Reddys Labs |
| 5 of 6 | |
|---|---|
| Drug Name | Larotid |
| PubMed Health | Amoxicillin (By mouth) |
| Drug Classes | Antibiotic |
| Drug Label | MOXATAG (amoxicillin extended-release) tablets for oral administration are provided as blue film-coated, oval shaped tablets that contain 775 mg of amoxicillin as the trihydrate and are printed with MB-111 on one side in black edible ink. Amoxi... |
| Active Ingredient | Amoxicillin |
| Dosage Form | For suspension |
| Route | Oral |
| Strength | 250mg/5ml; 125mg/5ml |
| Market Status | Prescription |
| Company | Dr Reddys Labs |
| 6 of 6 | |
|---|---|
| Drug Name | Moxatag |
| Active Ingredient | Amoxicillin |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | 775mg |
| Market Status | Prescription |
| Company | Pragma Pharms |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13498
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13201
Submission : 1998-04-30
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13481
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13207
Submission : 1998-04-30
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8845
Submission : 1990-11-15
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13215
Submission : 1998-04-30
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12895
Submission : 1998-03-11
Status : Inactive
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11451
Submission : 1995-04-14
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11483
Submission : 1995-04-28
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11481
Submission : 1995-04-28
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
Amoxicillin Trihydrate, Toansa, India: Powder Gr...
Certificate Number : CEP 2007-226 - Rev 05
Status : Valid
Issue Date : 2025-06-12
Type : Chemical
Substance Number : 260
Certificate Number : R1-CEP 2004-147 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2013-04-22
Type : Chemical
Substance Number : 260
Amoxicillin Trihydrate, Powder, Compacted And Mi...
Certificate Number : R0-CEP 1997-129 - Rev 00
Status : Withdrawn by EDQM Failure to CEP pro...
Issue Date : 2005-01-24
Type : Chemical
Substance Number : 260
Certificate Number : R1-CEP 2004-074 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2013-04-30
Type : Chemical
Substance Number : 260
Certificate Number : R1-CEP 1996-060 - Rev 03
Status : Withdrawn by EDQM Failure to CEP pro...
Issue Date : 2010-12-20
Type : Chemical
Substance Number : 260
Certificate Number : R1-CEP 2004-266 - Rev 01
Status : Withdrawn by EDQM Failure to CEP pro...
Issue Date : 2012-11-16
Type : Chemical
Substance Number : 260
Amoxicillin Trihydrate, Mexico, Powder Material,...
Certificate Number : R2-CEP 1995-030 - Rev 02
Status : Withdrawn by Holder
Issue Date : 2014-06-02
Type : Chemical
Substance Number : 260
Amoxicillin Trihydrate, For Veterinary Purposes ...
Certificate Number : R0-CEP 2007-018 - Rev 02
Status : Withdrawn by Holder
Issue Date : 2013-05-28
Type : Chemical
Substance Number : 260
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Vonoprazan is a novel potassium-competitive acid blocker (PCAB). It inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Voquezna Triple Pack
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Phathom Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 24, 2022
Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Phathom Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Evonik and Phathom Pharmaceuticals Partner to Produce Novel Acid-Blocker Vonoprazan
Details : Vonoprazan is a novel potassium-competitive acid blocker (PCAB). It inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions.
Product Name : Voquezna Triple Pack
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 24, 2022
Details:
Linaprazan Glurate is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Linaprazan Glurate,Amoxicillin Trihydrate
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 29, 2025
Lead Product(s) : Linaprazan Glurate,Amoxicillin Trihydrate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin
Details : Linaprazan Glurate is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 29, 2025
Details:
Linaprazan Glurate is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies.
Lead Product(s): Linaprazan Glurate,Amoxicillin Trihydrate,Clarithromycin,Bismuth Potassium Citrate,Esomeprazole Magnesium
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 19, 2025
Lead Product(s) : Linaprazan Glurate,Amoxicillin Trihydrate,Clarithromycin,Bismuth Potassium Citrate,Esomeprazole Magnesium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug Interaction Study on Linaprazan Glurate Capsules
Details : Linaprazan Glurate is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 19, 2025
Details:
Through the acquisition of Amoxicillin, an antibiotic targeting bacterial penicillin-binding protein, the deal aims to advance treatment for antibiotic-resistant infections.
Lead Product(s): Amoxicillin Trihydrate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Gaelic Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 11, 2025
Lead Product(s) : Amoxicillin Trihydrate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Gaelic Laboratories
Deal Size : Undisclosed
Deal Type : Acquisition
Gaelic Labs Acquires Athlone, Strengthens Beta Lactam Industry Leadership
Details : Through the acquisition of Amoxicillin, an antibiotic targeting bacterial penicillin-binding protein, the deal aims to advance treatment for antibiotic-resistant infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
December 11, 2025
Details:
Voquezna Triple Pak (vonoprazan) is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Helicobacter Infections.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Voquezna Triple Pak
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Phathom Pharmaceuticals | NRG Oncology
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 03, 2025
Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Phathom Pharmaceuticals | NRG Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1
Details : Voquezna Triple Pak (vonoprazan) is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Helicobacter Infections.
Product Name : Voquezna Triple Pak
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 03, 2025
Details:
Through the licensing deal for Omeprazole Magnesium, targeting Potassium-transporting ATPase, the agreement aims to advance treatment for H. pylori infection.
Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Talicia
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Cumberland Pharmaceuticals
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 20, 2025
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Cumberland Pharmaceuticals
Deal Size : $4.0 million
Deal Type : Licensing Agreement
RedHill Secures $4M Investment, U.S. Co-Commercialization Deal for Talicia
Details : Through the licensing deal for Omeprazole Magnesium, targeting Potassium-transporting ATPase, the agreement aims to advance treatment for H. pylori infection.
Product Name : Talicia
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 20, 2025
Details:
Through the licensing deal for Omeprazole Magnesium, targeting Potassium-transporting ATPase, the focus is on addressing Helicobacter pylori (H. pylori) infection.
Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Talicia
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: $1.8 million Upfront Cash: $0.2 million
Deal Type: Licensing Agreement October 08, 2025
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $1.8 million
Deal Type : Licensing Agreement
RedHill Biopharma inks $1.8 million Middle East licensing deal for Talicia
Details : Through the licensing deal for Omeprazole Magnesium, targeting Potassium-transporting ATPase, the focus is on addressing Helicobacter pylori (H. pylori) infection.
Product Name : Talicia
Product Type : Miscellaneous
Upfront Cash : $0.2 million
October 08, 2025
Details:
Bismuth is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Helicobacter Infections.
Lead Product(s): Bismuth,Metronidazole,Tetracycline,Omeprazole,Clarithromycin,Amoxicillin Trihydrate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 05, 2025
Lead Product(s) : Bismuth, Metronidazole, Tetracycline, Omeprazole, Clarithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Personalized vs Standard Care for Helicobacter Pylori Eradication in Veterans
Details : Bismuth is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Helicobacter Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 05, 2025
Details:
Linezolid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Syphilis, Congenital.
Lead Product(s): Linezolid,Amoxicillin Trihydrate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: University College Dublin | University of Stellenbosch | Malawi Liverpool Wellcome Programme | University of Sydney | Murdoch Childrens Research Institute | MRC CTU at UCL | PHPT/AMS Laboratory
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2025
Lead Product(s) : Linezolid,Amoxicillin Trihydrate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : University College Dublin | University of Stellenbosch | Malawi Liverpool Wellcome Programme | University of Sydney | Murdoch Childrens Research Institute | MRC CTU at UCL | PHPT/AMS Laboratory
Deal Size : Inapplicable
Deal Type : Inapplicable
Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis
Details : Linezolid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Syphilis, Congenital.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 10, 2025
Details:
Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.
Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Talicia
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 18, 2025
Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation
Details : Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.
Product Name : Talicia
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 18, 2025
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
D-4-Hydroxy-((3- methoxy-1-methyl- 3-oxo-1-propeny...
CAS Number : 69416-61-1
End Use API : Amoxicillin Trihydrate
About The Company : Zhejiang Apeloa Medical Technology Co., Ltd.(Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd.) is a medicinal industry enterprise integrating R&D, manufacturing...
CAS Number : 51997-51-4
End Use API : Amoxicillin Trihydrate
About The Company : Zhejiang Apeloa Medical Technology Co., Ltd.(Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd.) is a medicinal industry enterprise integrating R&D, manufacturing...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
Regulatory Info :
Registration Country : Netherlands
Brand Name :
Dosage Form : Hard Capsule
Dosage Strength : 500MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Netherlands
Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
Regulatory Info :
Registration Country : Netherlands
Brand Name :
Dosage Form : Dispersible Tablet
Dosage Strength : 500MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Netherlands
Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
Regulatory Info :
Registration Country : Netherlands
Brand Name :
Dosage Form : Dispersible Tablet
Dosage Strength : 750MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Netherlands
Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
Regulatory Info :
Registration Country : Netherlands
Brand Name :
Dosage Form : Dispersible Tablet
Dosage Strength : 1000MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Netherlands
Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
Regulatory Info :
Registration Country : Netherlands
Brand Name :
Dosage Form : Powder for Oral Suspension
Dosage Strength : 125MG/5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Netherlands
Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
Regulatory Info :
Registration Country : Netherlands
Brand Name :
Dosage Form : Powder for Oral Suspension
Dosage Strength : 250MG/5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Netherlands
Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
Regulatory Info :
Registration Country : Netherlands
Brand Name :
Dosage Form : Powder for Oral Suspension
Dosage Strength : 500MG/5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Netherlands
Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
Regulatory Info : Cancelled
Registration Country : Spain
Brand Name : Amoxicilina/Acido Clavulanico Centrient
Dosage Form : Powder For Oral Suspension
Dosage Strength : 500MG; 125 MG
Packaging :
Approval Date : 28-12-2016
Application Number : 81570
Regulatory Info : Cancelled
Registration Country : Spain
Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
Regulatory Info : Cancelled
Registration Country : Spain
Brand Name : Amoxicilina/Acido Clavulanico Centrient
Dosage Form : Powder For Oral Suspension
Dosage Strength : 875MG; 125 MG
Packaging :
Approval Date : 28-12-2016
Application Number : 81571
Regulatory Info : Cancelled
Registration Country : Spain
Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
Regulatory Info : Cancelled
Registration Country : Spain
Brand Name : Amoxicilina Centrient
Dosage Form : Powder For Oral Suspension
Dosage Strength : 250MG
Packaging :
Approval Date : 08-08-2018
Application Number : 81128
Regulatory Info : Cancelled
Registration Country : Spain
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Synergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.
RLD : No
TE Code :
Brand Name : AMOXICILLIN
Dosage Form : CAPSULE;ORAL
Dosage Strength : 500MG
Approval Date : 1988-02-25
Application Number : 62881
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Synergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.
RLD : No
TE Code :
Brand Name : AMOXICILLIN
Dosage Form : CAPSULE;ORAL
Dosage Strength : 250MG
Approval Date : 1988-02-25
Application Number : 62884
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : AMOXICILLIN
Dosage Form : CAPSULE;ORAL
Dosage Strength : 500MG
Approval Date : 1985-08-07
Application Number : 62528
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
AMOXICILLIN; CLAVULANATE POTASSIUM
Brand Name : AMOXICILLIN AND CLAVULANATE POTASSIUM
Dosage Form : FOR SUSPENSION;ORAL
Dosage Strength : 200MG/5ML;EQ 28.5MG BASE/5ML
Approval Date : 2011-12-20
Application Number : 201090
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : AMOXICILLIN
Dosage Form : TABLET;ORAL
Dosage Strength : 875MG
Approval Date : 2000-11-24
Application Number : 65059
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
AMOXICILLIN; CLAVULANATE POTASSIUM
Brand Name : AMOXICILLIN AND CLAVULANATE POTASSIUM
Dosage Form : FOR SUSPENSION;ORAL
Dosage Strength : 400MG/5ML;EQ 57MG BASE/5ML
Approval Date : 2003-03-19
Application Number : 65132
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : Yes
TE Code :
Brand Name : AMOXIL
Dosage Form : TABLET, CHEWABLE;ORAL
Dosage Strength : 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 1982-01-01
Application Number : 50542
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - 250MG;EQ 125MG BASE **...DOSAGE - TABLET;ORAL - 250MG;EQ 125MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50564
DOSAGE - TABLET;ORAL - 500MG;EQ 125MG BASE **...DOSAGE - TABLET;ORAL - 500MG;EQ 125MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50564
DOSAGE - FOR SUSPENSION;ORAL - 125MG/5ML;EQ 3...DOSAGE - FOR SUSPENSION;ORAL - 125MG/5ML;EQ 31.25MG BASE/5ML
USFDA APPLICATION NUMBER - 50575
DOSAGE - FOR SUSPENSION;ORAL - 250MG/5ML;EQ 6...DOSAGE - FOR SUSPENSION;ORAL - 250MG/5ML;EQ 62.5MG BASE/5ML
USFDA APPLICATION NUMBER - 50575
DOSAGE - TABLET;ORAL - 875MG;EQ 125MG BASE
USFDA APPLICATION NUMBER - 50720
DOSAGE - FOR SUSPENSION;ORAL - 200MG/5ML;EQ 2...DOSAGE - FOR SUSPENSION;ORAL - 200MG/5ML;EQ 28.5MG BASE/5ML
USFDA APPLICATION NUMBER - 50725
DOSAGE - FOR SUSPENSION;ORAL - 400MG/5ML;EQ 5...DOSAGE - FOR SUSPENSION;ORAL - 400MG/5ML;EQ 57MG BASE/5ML
USFDA APPLICATION NUMBER - 50725
DOSAGE - TABLET;ORAL - 500MG **Federal Regist...DOSAGE - TABLET;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50754
DOSAGE - TABLET;ORAL - 875MG **Federal Regist...DOSAGE - TABLET;ORAL - 875MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50754
DOSAGE - FOR SUSPENSION;ORAL - 600MG/5ML;EQ 4...DOSAGE - FOR SUSPENSION;ORAL - 600MG/5ML;EQ 42.9MG BASE/5ML
USFDA APPLICATION NUMBER - 50755
DOSAGE - CAPSULE, TABLET, CAPSULE, DELAYED RE...DOSAGE - CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL - 500MG;500MG;30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50757
DOSAGE - FOR SUSPENSION;ORAL - 200MG/5ML **Fe...DOSAGE - FOR SUSPENSION;ORAL - 200MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50760
DOSAGE - FOR SUSPENSION;ORAL - 400MG/5ML
USFDA APPLICATION NUMBER - 50760
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 1GM;...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 62.5MG BASE
USFDA APPLICATION NUMBER - 50785
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 775M...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 775MG
USFDA APPLICATION NUMBER - 50813
DOSAGE - CAPSULE, TABLET, CAPSULE, DELAYED RE...DOSAGE - CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL - 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50824
Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CD Formulation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Esteem Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Keval Exports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Neelkanth MineChem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nitika Pharmaceutical Specialities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Coating Systems & Additives
Fillers, Diluents & Binders
Thickeners and Stabilizers
Controlled & Modified Release
Disintegrants & Superdisintegrants
Lubricants & Glidants
Direct Compression
Granulation
Topical
Co-Processed Excipients
Film Formers & Plasticizers
Taste Masking
Solubilizers
Empty Capsules
API Stability Enhancers
Emulsifying Agents
Chewable & Orodispersible Aids
Vegetarian Capsules
Rheology Modifiers
Coloring Agents
Parenteral
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
US Patents
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
Analytical Methods
ABOUT THIS PAGE
66
PharmaCompass offers a list of Amoxicillin Trihydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Amoxicillin Trihydrate manufacturer or Amoxicillin Trihydrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Amoxicillin Trihydrate manufacturer or Amoxicillin Trihydrate supplier.
PharmaCompass also assists you with knowing the Amoxicillin Trihydrate API Price utilized in the formulation of products. Amoxicillin Trihydrate API Price is not always fixed or binding as the Amoxicillin Trihydrate Price is obtained through a variety of data sources. The Amoxicillin Trihydrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Amoxidal manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Amoxidal, including repackagers and relabelers. The FDA regulates Amoxidal manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Amoxidal API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Amoxidal manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Amoxidal supplier is an individual or a company that provides Amoxidal active pharmaceutical ingredient (API) or Amoxidal finished formulations upon request. The Amoxidal suppliers may include Amoxidal API manufacturers, exporters, distributors and traders.
click here to find a list of Amoxidal suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Amoxidal DMF (Drug Master File) is a document detailing the whole manufacturing process of Amoxidal active pharmaceutical ingredient (API) in detail. Different forms of Amoxidal DMFs exist exist since differing nations have different regulations, such as Amoxidal USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Amoxidal DMF submitted to regulatory agencies in the US is known as a USDMF. Amoxidal USDMF includes data on Amoxidal's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Amoxidal USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Amoxidal suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Amoxidal Drug Master File in Japan (Amoxidal JDMF) empowers Amoxidal API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Amoxidal JDMF during the approval evaluation for pharmaceutical products. At the time of Amoxidal JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Amoxidal suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Amoxidal Drug Master File in Korea (Amoxidal KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Amoxidal. The MFDS reviews the Amoxidal KDMF as part of the drug registration process and uses the information provided in the Amoxidal KDMF to evaluate the safety and efficacy of the drug.
After submitting a Amoxidal KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Amoxidal API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Amoxidal suppliers with KDMF on PharmaCompass.
A Amoxidal CEP of the European Pharmacopoeia monograph is often referred to as a Amoxidal Certificate of Suitability (COS). The purpose of a Amoxidal CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Amoxidal EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Amoxidal to their clients by showing that a Amoxidal CEP has been issued for it. The manufacturer submits a Amoxidal CEP (COS) as part of the market authorization procedure, and it takes on the role of a Amoxidal CEP holder for the record. Additionally, the data presented in the Amoxidal CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Amoxidal DMF.
A Amoxidal CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Amoxidal CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Amoxidal suppliers with CEP (COS) on PharmaCompass.
A Amoxidal written confirmation (Amoxidal WC) is an official document issued by a regulatory agency to a Amoxidal manufacturer, verifying that the manufacturing facility of a Amoxidal active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Amoxidal APIs or Amoxidal finished pharmaceutical products to another nation, regulatory agencies frequently require a Amoxidal WC (written confirmation) as part of the regulatory process.
click here to find a list of Amoxidal suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Amoxidal as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Amoxidal API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Amoxidal as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Amoxidal and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Amoxidal NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Amoxidal suppliers with NDC on PharmaCompass.
Amoxidal Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Amoxidal GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Amoxidal GMP manufacturer or Amoxidal GMP API supplier for your needs.
A Amoxidal CoA (Certificate of Analysis) is a formal document that attests to Amoxidal's compliance with Amoxidal specifications and serves as a tool for batch-level quality control.
Amoxidal CoA mostly includes findings from lab analyses of a specific batch. For each Amoxidal CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Amoxidal may be tested according to a variety of international standards, such as European Pharmacopoeia (Amoxidal EP), Amoxidal JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Amoxidal USP).
